

REVIEW

Open Access

Current management and prognostic features for gastrointestinal stromal tumor (GIST)

Gurpreet Lamba, Ridhi Gupta, Byung Lee, Samir Ambrale and Delong Liu*

Abstract

Stromal or mesenchymal neoplasms affecting the gastrointestinal (GI) tract have undergone a remarkable evolution in how they are perceived, classified, approached, diagnosed and managed over the last 30 years. Gastrointestinal stromal tumors (GIST) account for approximately 1% to 3% of all malignant GI tumors. The clinical features can vary depending on the anatomic location, size and aggressiveness of the tumor. Metastatic GIST represents a successful example of molecular targeted therapy. In this comprehensive review, we discuss the epidemiology, clinical features and diagnostic modalities for GIST. We also describe treatment options for early stage, locally advanced and metastatic GIST. Indications for neoadjuvant and adjuvant therapy along with duration of therapy are also explained. A brief discussion of latest biomarkers and updates from recent meetings is also provided.

Introduction

Stromal or mesenchymal neoplasms affecting the GI tract have undergone a remarkable evolution in how they are perceived, classified, approached, diagnosed and managed over the last 30 years. A major breakthrough occurred with the discovery of expression of the CD117 antigen by almost all gastrointestinal stromal tumors (GIST)[1]. The other group of spindle cell neoplasms arising in the GI tract includes lipomas, schwannomas, hemangiomas, usual leiomyomas and leiomyosarcomas are typically CD117-negative [2]. The CD117 molecule is part of the KIT (c-kit) receptor tyrosine kinase that is a product of the KIT proto-oncogene (Figure 1). GIST research and clinical care sets another great example of translational research that turns laboratory discovery to successful clinical application. From this fundamental mechanistic understanding of GIST, a series of worldwide investigations and trials have developed novel and effective ways to approach patients with this disease. In this review, we discuss the basics of GIST and highlight recent advances and their relevance to current clinical practice as well as future directions.


Epidemiology

GISTs account for approximately 1% to 3% of all malignant GI tumors [3]. Epidemiologic data such as that from Surveillance, Epidemiology and End Results (SEER) program are difficult to interpret since the earlier definition of "malignant GIST" was derived from criteria published in 1990, before GIST was molecularly characterized [4]. The estimated incidence of GIST has been revised upward to approximately 5,000 new cases per year in the United States (US) [5,6]. The most dependable international epidemiologic data are from population-based studies that reexamined all cases of potential GIST [7-10]. These studies reported annual incidence of GIST ranging from 11 to 14.5 per million population. More recent studies suggest that the incidentally detected sub-centimeter gastric GIST lesions may be more frequent than expected [11,12].

Clinical presentation

The clinical features can vary depending on the anatomic location, size and aggressiveness of the tumor. Most symptomatic patients have tumors larger than 5 cm in maximal dimension. In a series of cases with leiomyomas and leiomyosarcoma (without separation of the GISTs), there were three major presentations [13], GI bleeding (40%), abdominal mass (40%) and abdominal pain (20%). Two-thirds of patients had GI bleeding while 25 to 40% presented with an intestinal obstruction. Intestinal perforation can also occur uncommonly. Rare patients have been described

* Correspondence: delong_liu@nycmc.edu
Division of Oncology/Hematology, New York Medical College and
Westchester Medical Center, Valhalla, NY 10595, USA



who present with severe hypoglycemia due to paraneoplastic production of insulin like growth factor II [14]. Other symptoms at presentation may include nausea, vomiting, anorexia, and weight loss. The vast majority of GIST metastases at presentation are intra-abdominal, either to the liver, omentum or peritoneal cavity [15]. Metastases to lymph nodes or to extra-abdominal sites via lymphatics are rare.

Diagnostic imaging

GIST should always be among the differential diagnosis of an intra-abdominal non-epithelial malignancy. CT is essential for evaluating the primary tumor and for accurate staging. Magnetic resonance imaging (MRI) has a comparable diagnostic yield [16] and lacks radiation exposure. However, CT is preferred initially for screening and staging. CT is better at global evaluation of the abdomen, especially the hollow viscera, than MRI. MRI may be preferred for GISTs at specific sites, such as rectum or liver. Tumors that are greater than 5 cm, lobulated, enhance heterogeneously, and have mesenteric fat infiltration, ulceration, regional lymphadenopathy, or an exophytic growth pattern on CT are more likely to metastasize [17-21]. In contrast, GISTs with less metastatic potential tend to enhance in a homogeneous pattern, and often show an endoluminal growth pattern. CT or MRI scanning can assess the decrease in lesion density which can be an early marker of beneficial response in GIST patients treated with TKI drugs [22]. Routine clinical practice rarely requires Positron Emission Tomography (PET) imaging of GIST for clinical care [23]. PET imaging may have the advantage of detecting small lesions at least 1 cm in size because neither the normal bowel nor omentum takes up the

fluorodeoxyglucose (FDG) tracer with excess avidity. The reported sensitivity of PET for GIST is 86 to 100% [24,25]. PET can be useful for detecting an unknown primary site or resolving ambiguities from CT [26]. On upper GI endoscopy, a smooth, mucosa-lined protrusion of the bowel wall, with or without signs of bleeding and ulceration may be seen [27]. However, endoscopic biopsies using standard techniques usually do not obtain sufficient tissue for a definite diagnosis [28]. Endoscopic ultrasound (EUS) -guided fine-needle biopsy forceps also may not yield enough tissue, but might exclude other lesions that arise sub-mucosally. Snare biopsies can result in perforation and generally should be avoided except in carefully selected cases [28]. A preoperative biopsy is not generally recommended for a resectable lesion in which there is a high suspicion for GIST, and the patient is otherwise operable. However, a biopsy should be done to confirm the diagnosis particularly when metastatic disease is present or suspected. If preoperative imatinib is considered in a patient who has a large locally advanced lesion thought to represent GIST, a biopsy should be done. An EUS-guided biopsy (in carefully selected patients and preferably of the primary lesions) is more desirable than a percutaneous biopsy [29].

Histopathology and cytology

Differentiation between GISTs and other tumors is typically based upon immunohistochemistry (IHC) and molecular analysis. Histologic findings seen on hematoxylin and eosin-stained sections do not reliably or specifically relate to the immunophenotype nor the molecular genetics of the lesions [30]. GISTs characteristically stain positive for CD117 antigen (KIT) on IHC assays. The level of expression can vary from generally diffuse and strong (most common in the spindle cell subtype) to focal and weakly positive in a dot-like pattern (the epithelioid subtype) [5]. CD34 expression is not specific for GIST and it can also be seen in desmoid tumors [5,31,32]. About 95% of GISTs are KIT-positive, while 60 to 70% are positive for CD34, 30 to 40% are positive for smooth muscle actin, 5% for S-100 protein, and 1 to 2% are positive for desmin or keratin [2,5,32]. Identification of CD117-negative GIST remains a diagnostic challenge, and these are most likely to be driven by alternative kinases like PDGFRA [33]. The antigen known as DOG-1 ("discovered on GIST-1") can also help to identify certain KIT-negative GIST lesions as DOG-1 expression is quite specific for GIST [34,35].

Prognostic features of GIST

The current consensus is to treat all GISTs, including those with a benign appearance by conventional histopathologic criteria, as having the potential to behave in a malignant fashion [5,23]. This is due to the biologic

behavior of GIST, which can be highly variable and with long follow-up, virtually all GISTs have the potential for malignant behavior, even those 2 cm or less with bland histologic features [2]. Thus, it is not appropriate to define any GIST as "benign" per se [5,36,37]. The most reliable prognostic factors for GIST are size of the primary tumor and the mitotic index. Additionally, recurrence and survival rates can be affected by the location of the primary GIST lesion (e.g. with small bowel and rectal primary GIST demonstrate worse prognosis than gastric GISTs) [36,37]. PDGFRA mutations (almost always in gastric primaries) appear to be a very favorable prognostic factor for low risk of recurrence [38]. Among patients with GIST, histologic type may also impact prognosis. In a report of 48 patients, the five-year recurrence-free survival rate was significantly higher among patients with spindle cell as compared to epithelioid or mixed histology [39]. However, others report a prognostic influence of the degree of cellularity but not histologic subtype [40,41].

Management paradigms for early-stage GIST

The natural history of early-stage GIST has been documented in single-institution studies. Two hundred patients with GIST were followed prospectively at the Memorial Sloan-Kettering Cancer Center [15]. Eighty of these patients who had primary disease were managed with complete surgical resection. This group of patients demonstrated a 5-year disease-specific survival rate of 54%. On multivariate analysis, large tumor size (>10 cm) was the only negative predictive factor on disease-specific survival. Definitive surgery remains the treatment of choice for patients with localized GIST. Complete surgical resection is recommended for small gastric GISTs <2 cm at high risk of recurrence based upon EUS appearance (irregular borders, cystic spaces, ulceration, echogenic foci, or heterogeneity in appearance). For tumors that lack these features, endoscopic surveillance is an option. However, initial therapy with imatinib may be preferred if a tumor is borderline resectable, or if resection would necessitate extensive organ disruption. There is no specific consensus or guideline for the use of neoadjuvant imatinib at this time. However, this could serve as the initial therapeutic intervention, with follow-up at close intervals to ensure appropriate response to therapy. In these situations, early assessment of therapeutic response by ¹⁸F-DG-PET scanning could be very valuable to confirm the response to imatinib. After maximal response (usually occurring within 4 to 6 months), definitive surgery could be performed [42].

Adjuvant therapy for resected early-stage GIST

A large multicenter landmark phase 3 trial (ACOSOG study Z9001) appears to support the use of imatinib

therapy in patients with larger, fully resected, primary localized GIST lesions at significant risk of relapse [43]. Seven hundred and thirteen adults with a completely resected primary GIST (>= 3 cm, KIT+) were randomly assigned to one year of adjuvant imatinib (400 mg daily) or placebo [43]. The trial was stopped at an early, pre-planned, event-based interim analysis because of the positive outcome. At a median follow-up of 20 months, 30 patients in the imatinib group recurred or died, versus 70 in the placebo group (8 versus 20%). The one-year relapse-free survival (RFS) rate was 98 versus 83% favoring imatinib, with a hazard ratio for RFS of 0.35 (95% CI 0.22 to 0.53). In a later analysis, the benefit was greatest in those with high-risk disease (relapse rate 47 versus 19% for placebo and imatinib, respectively); for moderate risk disease it was 14 versus 5%, respectively [44]. Despite prolonged RFS, no benefit in overall survival (OS) was noted with short follow-up. Furthermore, after the study was unblinded, all patients randomized to placebo were allowed to crossover to active treatment, thus obscuring any potential differences in overall survival between the groups. Thus, it remains unclear whether imatinib is simply delaying or really preventing relapses. The trial tested only the 400 mg daily dose. Patients with advanced GIST and KIT exon 9 mutations do better with 800 mg daily doses. Whether doses greater than 400 mg should be used in the adjuvant setting will require prospective study. Although they were excluded, these results may also be significant for the 4% of patients with GISTs that lack KIT overexpression, but have mutations in KIT or PDGFRA, and can respond to imatinib [45]. Contrary to this, patients who lack detectable KIT or PDGFRA mutations or who have specific mutations that are known to be resistant to imatinib may not benefit. Whether such patients should be identified prospectively and specifically excluded from receiving adjuvant imatinib is unclear.

The FDA approved the use of imatinib as adjuvant therapy without any qualification or restriction following resection of primary GIST ≥3 cm in size, but the European Medicines Agency approved adjuvant imatinib only for the subset of GIST patients with primary disease that is judged to be "at significant risk of recurrence" following resection.

Estimation of recurrence risk

Several criteria have been proposed, originally to classify the malignant potential of a GIST. Tumor size, mitotic rate, and site of tumor origin have gained the greatest acceptance as being predictive of outcome [46]. Risk stratification models have also been proposed to distinguish prognosis in resected GIST [39]. Tumors arising from the small bowel, colon, rectum, or mesentery are associated with less favorable outcomes than those

arising from the stomach [37]. Thus, each case must be approached individually, balancing the estimated probability of a disease recurrence.

Adjuvant imatinib for 1 year certainly has a major impact on disease control rates, but these differences appear to fade with increased rates of recurrence noted on discontinuation of the imatinib dosing. It is possible that a longer duration of adjuvant therapy might further improve clinical outcomes. A small study of adjuvant therapy for 2 years in Seoul, Korea has shown much higher rates of disease control than in the 1-year study, consistent with biological expectations [47]. The results of a trial by the Scandinavian Sarcoma Group (SSG) XVIII trial were presented at the 2011 American Society of Clinical Oncology (ASCO) meeting and then published in 2012. This trial compared 36 versus 12 months of imatinib (400 mg daily) in 400 patients with high-risk resected GIST [48]. High-risk was defined as having at least one of: tumor size >10 cm, mitotic count >10/50 high-power fields (hpf), tumor size >5 cm with mitotic rate >5/50 hpf, or tumor rupture. About one-half of the enrolled patients had gastric primary tumors. At a median follow-up of 54 months, prolonged treatment was associated with a significant improvement in RFS, the primary endpoint (five-year RFS 66 versus 48%, HR 0.46, 95% CI 0.32 to 0.65) as well as OS (92 versus 82%, HR 0.45, 85% CI 0.22 to 0.89). However, twice as many patients discontinued imatinib for reasons other than disease progression in the prolonged therapy group (26 versus 13%). This dataset attempts to establish 36 months of adjuvant imatinib as a new standard for patients with high-risk resected GIST. In both groups, within 6 to 12 months of discontinuing adjuvant imatinib, rates of disease recurrence were similarly increased. This and previous findings seem to support the notion that recurrences are just delayed, rather than being prevented. The question now is whether treatment should be continued for longer than three years. One study assessed cost-effectiveness of 3 years versus 1 year of adjuvant imatinib in the US from a payer's perspective [49]. They reported total lifetime cost per patient at \$302,100 with 3 years versus \$217,800 for 1 year of imatinib therapy. They also found that patients on 3 years of imatinib had higher quality-adjusted life years (QALYs). Thus, incremental cost effectiveness ratio of 3 years versus 1 year of imatinib therapy was \$62,600/QALY. At a threshold of \$100,000/QALY, 3 year imatinib therapy was cost-effective. At the same meeting Deflin and colleagues reported on the comparison of the clinical benefit of an adjuvant therapy in GIST with other adjuvant cancer therapies [50]. They showed that imatinib has one of the lowest number needed to treat amongst other adjuvant treatments, at 1 and 3 year of follow-up. Thus, both clinical and economic results now suggest treating surgically

resected GIST patients with 3 years of imatinib would result in improved quality-adjusted and OS.

The Intergroup EORTC 62024 trial with randomization between two years of imatinib and observation alone has been completed and is awaiting data maturation. OS is the primary end point. A single-arm phase II five-year adjuvant imatinib trial, PERSIST5, has also completed accrual; data probably will not be available for several years.

Additionally, it is also important to assess whether certain GIST genotypic subsets benefit more—or fail to benefit at all—from adjuvant therapy with TKIs. The ACOSOG Z9001 randomized trial has confirmed certain differences between the behaviors of genetically different forms of GIST. The KIT exon 11 deletion confers a much higher risk of relapse compared with other mutational subtypes in the placebo arm, but these exon 11 mutants benefit from adjuvant imatinib to ablate this added risk [38]. The PDGFRA-driven GISTs are often more aggressive in the metastatic setting, however, they are remarkably indolent with a low risk for relapse following resection of limited-stage primary disease, similar to the wild type GIST. Given the potential toxicities and costs of imatinib, as well as the tremendous success of imatinib for recurrent disease, it is very important that adjuvant studies of imatinib be completed and analyzed in the context of molecular subtyping.

Neoadjuvant therapy

There are no published randomized trials addressing the benefit of neoadjuvant imatinib in the management of GIST. Since 2003, several case reports and small retrospective series have been published. These include a mix of patients with borderline resectable and unresectable primary disease, as well as metastatic and locally recurrent disease that is potentially amenable to gross resection [51-57].

The multicenter RTOG (Radiation Therapy Oncology Group) 0132/ACRIN (American College of Radiology Imaging Network) 6665 trial assessed neoadjuvant imatinib either in primary resectable GIST or as a planned pre-operative cytoreduction agent for metastatic GIST [58]. Patients with primary GIST (≥ 5 cm, Group A) or operable metastatic/recurrent GIST (≥ 2 cm, Group B) were treated with neoadjuvant imatinib (600 mg/day) for approximately two months and maintenance imatinib after surgery for 2 years. The clinical outcomes including progression-free survival (PFS), disease-specific survival (DSS), and overall survival (OS) at a median follow-up of 5.1 years were presented at ASCO 2011 meeting [59]. The authors correlated these endpoints with duration of imatinib therapy. Sixty-three patients were originally entered (53 analyzable). There were 31 patients in Group A and 22 in Group B. Estimated 5-year PFS and DSS were 57% A, 30% B; and 77% A, 77% B, respectively. Estimated 5-year OS

was 77% for A, and 68% for B. Median time to progression had not been reached for Group A and was 4.4 years for Group B. In Group A, 7/11 patients progressed > 2 years from registration; 6/7 progressing patients had stopped imatinib prior to progression. In Group B, 10/13 patients progressed >2 years from registration; 6/10 progressing patients had stopped imatinib prior to progression. This long-term analysis suggested a high percentage of patients progressed after discontinuation of 2-year maintenance imatinib therapy following surgical resection. This trial confirmed the safety of neoadjuvant imatinib. The available data from patients treated for advanced disease suggest that maximal radiographic response to imatinib generally occurs within three to nine months.

Data from retrospective series also support the benefit of initial imatinib therapy [52-56,60]. The largest experience consisted of 46 patients who underwent surgery after imatinib. Eleven patients had a locally advanced primary tumor, while 35 had recurrent or metastatic disease [52]. All 11 patients who were treated for a locally advanced primary tumor (median 12 months of imatinib prior to resection had one complete and eight partial responses as assessed by CT) successfully underwent complete surgical resection. There was one complete pathologic response. At a median follow-up of 19.7 months post-resection, all 11 were alive and ten of them were recurrence-free. There were 11 partial responses among the 35 patients treated for recurrent/metastatic disease. Eleven patients were able to undergo a complete resection including two with a complete pathologic response. Patients with an objective partial response to imatinib (by CT) were significantly more likely to undergo a complete resection. All eleven of the completely resected patients were alive at a median follow-up of 30.7 months, but six recurred at a median of 15 months, despite continuation of imatinib therapy.

A small trial suggested response rates of up to 70% after very brief periods of neoadjuvant imatinib (three to seven days), as assessed by FDG-PET and dynamic CT [61]. However, in this small prospective randomized phase II trial, there was no evidence of histologic cytoreduction (and therefore, no potential benefit in terms of reduced tumor bulk) from ≤ 7 days of neoadjuvant imatinib, and no suggestion that intra-operative blood loss was reduced, even though blood flow to the tumor was reduced as measured by dynamic CT. Thus, the clinical benefit of very short periods of neoadjuvant imatinib (termed "nano-neoadjuvant therapy") [62] is unproven. It did prove that radiographic responses and tumor cell apoptosis occur within the first week of imatinib therapy.

Guidelines from the NCCN recommend initial treatment with imatinib for patients with marginally resectable tumors and for those who have potentially resectable disease but with the risk of significant morbidity. A daily dose of 400 mg per day is the usual approach, although if a KIT

exon 9 mutation is identified, dose escalation to 800 mg per day is reasonable. This is also recommended in ESMO guidelines [63].

Management of metastatic, unresectable or recurrent GIST

Various mechanisms are responsible for the resistance of GISTs to conventional cytotoxic chemotherapy. In one study evaluating the differences in outcome between GIST and leiomyosarcomas, significantly higher levels of expression of P-glycoprotein (38.4% vs. 13.4%) and MRP1 (35.4% vs. 13.3%) were demonstrated in the GIST cells [64].

During the 1990's, screening studies [65-67] demonstrated that a signal transduction inhibitor 571 (STI 571, imatinib mesylate) inhibits the tyrosine kinase activity of BCR-ABL as well as KIT. A multicenter US-Finland collaborative study enrolled 147 patients with metastatic GIST between July 2000 and April 2001 [68]. Radiographic responses were seen within six months in 54% patients. These results along with the outcomes of the European Organization for Research and Treatment of Cancer (EORTC) trial 75 [69] confirmed the unparalleled activity of imatinib in controlling metastatic GIST. Despite these excellent results complete responses are rare (less than 10%), and most patients who initially respond ultimately acquire resistance via additional mutations in KIT. The median time to progression is roughly two to three years [68,70-72], although it is longer in other series [73].

Correlative science studies have reported that the type of mutation in KIT and PDGFRA correlates with clinical response [74-77]. High dose imatinib may preferentially benefit patients with exon 9 mutations [77,78]. However, no differences in OS between low-dose and high-dose imatinib in patients with exon 9 mutations was seen [79].

Rapid disease progression was seen within months after the imatinib is stopped [80,81]. At ASCO 2011, BFR 14 trial reported the effect of interruption of imatinib therapy in patients with GIST [82]. At the same meeting, Domont et al. reported the influence of imatinib interruption and reintroduction on tumor burden in patients with GIST on the BFR 14 trial. Among randomized patients with imatinib interruption 49% experienced progressive disease of the known tumor while 51% had new lesions with concomitant progression of known lesions [83]. Thus, continuous therapy until disease progression (or lifelong if disease does not progress) is currently standard of care.

Imatinib can rapidly and dramatically decrease tumor avidity for ^{18}F FDG [84-86]. With PET imaging, the down-modulation of tumor avidity for FDG is far earlier than changes noticeable on CT scanning [68,84,86]. Thus PET scans can aid in the detection of primary and

secondary imatinib resistance. CT criteria using either no growth in tumor size or a combination of tumor density and size criteria have shown a close correlation with the predictive value results of FDG-PET [22,87]. Imatinib therapy can also change the density of tumor masses in GIST [22,68,88]. This is an important early clinical marker of antitumor activity [89,90].

Resistance to imatinib

Clonal evolution of resistant GIST may be detected after a durable objective response and disease control. Several mechanisms of resistance to imatinib in GIST may exist [91,92]. Pharmacokinetic variability may also contribute to drug resistance [93]. Limited clonal progression appears as the first sign of resistance to imatinib [55,92,94]. Dose escalation from imatinib 400 mg daily may be considered for those with clear evidence of disease progression [45,95]. Sunitinib targets multiple tyrosine kinases, including the vascular endothelial growth factor receptors and PDGFR. An increasing number of reports indicate efficacy for the multi-targeted TKI sunitinib in imatinib-refractory or intolerant patients [95-98]. Sunitinib has become the current standard of care for patients who have failed imatinib.

As with imatinib, the clinical activity of sunitinib is significantly influenced by the specific mutation type. Resistance to sunitinib shares similar pathogenetic mechanisms to those identified in imatinib failure, with acquisition of secondary mutations after an extended initial response to the drug [99].

Sorafenib and other TKIs (i.e. sorafenib, dasatinib, motesanib, nilotinib) have been studied in refractory GIST or after resistance to imatinib and/or sunitinib [1,100-105]. The efficacy of sorafenib was addressed in a multicenter phase II trial involving patients with either imatinib or imatinib and sunitinib-refractory GIST [106]. In a preliminary report presented at the 2011 ASCO GI Cancers symposium, the disease control rate (defined as the proportion of patients without progression as the best radiologic response) was 68%, and median PFS was 5.2 months.

Nilotinib was studied in a randomized phase 3 clinical trial (ENEST g3) [107]. In this trial nilotinib was compared to a heterogeneous control arm in patients advanced/metastatic GIST who had failed imatinib and sunitinib. The control arm included best supportive care with physician choice to continue or stop imatinib or sunitinib. It failed to show significant benefit for nilotinib. Some of the most promising new approaches to overcome resistance to TKIs in GIST include targeting multiple levels of the signal transduction cascade by combining agents. This has been done, for example, by combining a kinase inhibitor such as imatinib with an inhibitor of the mTOR downstream signaling partner

using the mTOR inhibitor everolimus [108]. Other strategies that are being explored include the inhibition of other pathways critical to the molecular processing of the mutant KIT or PDGFRA oncoproteins, such as the chaperone function of the heat shock protein-90 system. By inhibiting heat shock protein-90, preclinical and early clinical studies have already documented antineoplastic effects on kinase-inhibitor-resistant GIST both in vitro and in patients with progressive disease [109,110].

New prognostic features

The survival was higher in GIST patients who had PDGFRA mutation as compared to KIT mutations. In patients with KIT mutations, point mutations and duplication in KIT axon 11 had better survival than GIST with other KIT mutations [111].

In a single center study of GIST patients who underwent curative surgery and were not treated with imatinib, the 2 year RFS was lower in patients who had both 557 and 558 codon mutations than in those with either 557 or 558 mutated ($p = 0.03$) [112].

Hypertension (HTN) is a side effect of drugs with VEGF signaling pathway inhibition. The relationship between sunitinib-associated HTN and treatment efficacy was analyzed. The results significantly favored the patients who developed HTN while on treatment with Sunitinib. These patients had significantly prolonged OS, PFS and TTP as compared to patients who did not develop HTN. Development of HTN during sunitinib therapy may therefore be used as a biomarker for anti-tumor efficacy [113].

At ASCO GI 2012, a mitotic index of 5/50 HPF was reported to be equivalent to a standardized uptake value (SUV) of 4.3, and a Ki67 labeling index of 5 was equivalent to SUV of 6.3 on a PET-CT. Thus, an SUV of 5 can predict the malignant potential between the high and low/intermediate risk [114].

D-dimer may be another potential marker in GIST [115]. Radiological progression (rPD) was associated with higher d-dimer levels. D-dimer levels <1000 had a negative predictive value for rPD of 85%. Thus, d-dimer test may reduce the burden of CT scanning in a useful percentage of patients but will require further validation.

Recent trends

Billimoria et al. reported the evolution of multimodality management of GIST with adjuvant and neoadjuvant therapy. They found that between 2001 and 2007 use of adjuvant therapy with imatinib increased from 27% to 47%. Use of neo-adjuvant therapy increased from 0% to 15% in patients with tumors >6 cm [116]. Although the incidence of GIST increased from 1998 to 2001, it remained stable from 2001 to 2007. This period also saw a significant decrease in patients referred for surgery. Survival of patients

diagnosed in 2005–2007 group improved over those diagnosed from 2002–2004 for both resected and unresected tumor, with resection of the tumor being an independent predictor of survival [117].

Italiano and co-workers reported the pattern of care, prognosis and survival in patients treated with first line Imatinib or second line Sunitinib in patients with GIST over 9 centers, including 176 patients. In the preliminary results they found that patients having secondary mutations and low serum albumin levels had the worst outcome [118].

Updates from the BFR 14 trial

BFR 14 is a prospective multicenter study from 2002 to 2009 which enrolled 434 patients. Blesius et al. reviewed 236 patients who were started on imatinib 400 mg daily and had been on it for 5 years. Patients who did not show any progression were retrospectively analyzed. They found that patients with small tumor volume at inclusion, good performance status, having exon 11 mutation in vicinity of codon 557–558 have higher sensitivity to imatinib and have a prolonged outcome as compared to other patients [119]. Bertucci and associates investigated factors predicting long term prognosis in patients with advanced GIST on the BFR 14 trial. The study found that female sex, performance status of 0, platelet count <400,000/dl, lymphocyte count >1500/mm³ were independent predictors of overall survival. Patients with CD 34 positivity on tumors have a better PFS [120].

Conclusions and future directions

With the molecular signature of CD117/KIT mutation, GIST has provided a great model for targeted therapy. Novel targeted agents are being explored [1]. Combination therapy of TKI inhibitors either concurrently or sequentially with agents of different classes may have synergistic effects. It is therefore predictable that further clinical research by combining agents with novel mechanisms of action for this challenging malignancy will be forthcoming [121–124].

Competing interests

The authors have no conflicts of interests.

Acknowledgements

This study was partly supported by the NYMC Blood Diseases fund (DL).

Authors' contributions

SA, RG, BL contributed to data preparation. GL and DL were involved in concept design, data collection, and manuscript preparation. All authors reviewed and assisted in revising the manuscript. All authors read and approved the final manuscript.

Received: 25 May 2012 Accepted: 18 June 2012

Published: 18 June 2012

References

1. Lamba G, et al: Recent advances and novel agents for gastrointestinal stromal tumor (GIST). *J. Hematol & Oncol* 2012, **5**:21.

2. Rubin BP, Fletcher JA, Fletcher CD: Molecular Insights into the Histogenesis and Pathogenesis of Gastrointestinal Stromal Tumors. *Int J Surg Pathol* 2000, **8**(1):5–10.
3. Cassier PA, et al: A prospective epidemiological study of new incident GISTs during two consecutive years in Rhone Alpes region: incidence and molecular distribution of GIST in a European region. *Br J Cancer* 2010, **103**(2):165–170.
4. Tran T, Davila JA, El-Serag HB: The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. *Am J Gastroenterol* 2005, **100**(1):162–168.
5. Fletcher CD, et al: Diagnosis of gastrointestinal stromal tumors: A consensus approach. *Hum Pathol* 2002, **33**(5):459–465.
6. Miettinen M, et al: Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. *Hum Pathol* 2002, **33**(5):478–483.
7. Nilsson B, et al: Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. *Cancer* 2005, **103**(4):821–829.
8. Tryggvason G, et al: Gastrointestinal stromal tumors in Iceland, 1990–2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. *Int J Cancer* 2005, **117**(2):289–293.
9. Goettsch WG, et al: Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. *Eur J Cancer* 2005, **41**(18):2868–2872.
10. Tzen CY, et al: Incidence of gastrointestinal stromal tumor: a retrospective study based on immunohistochemical and mutational analyses. *Dig Dis Sci* 2007, **52**(3):792–797.
11. Kawanowa K, et al: High incidence of microscopic gastrointestinal stromal tumors in the stomach. *Hum Pathol* 2006, **37**(12):1527–1535.
12. Agaimy A, et al: Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. *Am J Surg Pathol* 2007, **31**(1):113–120.
13. Chou FF, Eng HL, Sheen-Chen SM: Smooth muscle tumors of the gastrointestinal tract: analysis of prognostic factors. *Surgery* 1996, **119**(2):171–177.
14. Pink D, et al: Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors: a report of two cases. *J Clin Oncol* 2005, **23**(27):6809–6811.
15. DeMatteo RP: The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). *Ann Surg Oncol* 2002, **9**(9):831–839.
16. Scarpa M, et al: A systematic review on the clinical diagnosis of gastrointestinal stromal tumors. *J Surg Oncol* 2008, **98**(5):384–392.
17. Chun HJ, et al: Gastrointestinal leiomyoma and leiomyosarcoma: CT differentiation. *J Comput Assist Tomogr* 1998, **22**(1):69–74.
18. Levy AD, et al: Gastrointestinal stromal tumors: radiologic features with pathologic correlation. *Radiographics* 2003, **23**(2):283–304. 456; quiz 532.
19. Ghanem N, et al: Computed tomography in gastrointestinal stromal tumors. *Eur Radiol* 2003, **13**(7):1669–1678.
20. Burkill GJ, et al: Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. *Radiology* 2003, **226**(2):527–532.
21. Hatch GF 3rd, et al: Tumors of the esophagus. *World J Surg* 2000, **24**(4):401–411.
22. Choi H, et al: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. *J Clin Oncol* 2007, **25**(13):1753–1759.
23. Demetri GD, et al: NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. *J Natl Compr Canc Netw* 2010, **8**(Suppl 2):S1–S41. quiz S42–4.
24. Gayed I, et al: The role of 18 F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. *J Nucl Med* 2004, **45**(1):17–21.
25. Kamiyama Y, et al: 18 F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. *World J Surg* 2005, **29**(11):1429–1435.
26. Demetri GD, et al: NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines. *J Natl Compr Canc Netw* 2007, **5**(Suppl 2):S1–S29. quiz S30.

27. Pihdorecky I, et al: Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. *Ann Surg Oncol* 2000, **7**(9):705–712.
28. Tio TL, Tytgat GN, den Hartog FC: Jager, Endoscopic ultrasonography for the evaluation of smooth muscle tumors in the upper gastrointestinal tract: an experience with 42 cases. *Gastrointest Endosc* 1990, **36**(4):342–350.
29. Avritscher R, Gupta S: Gastrointestinal stromal tumor: role of interventional radiology in diagnosis and treatment. *Hematol Oncol Clin North Am* 2009, **23**(1):129–137. ix.
30. van Roggen JF Graadt, van Velthuysen ML, Hogendoorn PC: The histopathological differential diagnosis of gastrointestinal stromal tumours. *J Clin Pathol* 2001, **54**(2):96–102.
31. Kindblom LG, et al: Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. *Am J Pathol* 1998, **152**(5):1259–1269.
32. Hirota S, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. *Science* 1998, **279**(5350):577–580.
33. Heinrich MC, et al: PDGFRA activating mutations in gastrointestinal stromal tumors. *Science* 2003, **299**(5607):708–710.
34. Miettinen M, Wang ZF, Lasota J: DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. *Am J Surg Pathol* 2009, **33**(9):1401–1408.
35. West RB, et al: The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. *Am J Pathol* 2004, **165**(1):107–113.
36. Miettinen M, Lasota J: Gastrointestinal stromal tumors: pathology and prognosis at different sites. *Semin Diagn Pathol* 2006, **23**(2):70–83.
37. Huang HY, et al: A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome. *Surgery* 2007, **141**(6):748–756.
38. Corless CL, et al: Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. *ASCO Meeting Abstracts* 2010, **28**(15_suppl):10006.
39. Singer S, et al: Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. *J Clin Oncol* 2002, **20**(18):3898–3905.
40. Reith JD, et al: Extragastric (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. *Mod Pathol* 2000, **13**(5):577–585.
41. Martin J, et al: Deletions affecting codons 557–558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). *J Clin Oncol* 2005, **23**(25):6190–6198.
42. DeVita VT, Lawrence TS, Rosenberg SA: *DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology*. 9th edition. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011:2638. xlvii.
43. Dematteo RP, et al: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. *Lancet* 2009, **373**(9669):1097–1104.
44. Blackstein ME, et al: Risk assessment for tumor recurrence after surgical resection of localized primary gastrointestinal stromal tumor (GIST): North American Intergroup phase III trial ACOSOG Z9001. *ASCO GI Cancer Symposium* 2010, **28**(suppl 4):6.
45. Blanke CD, et al: Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. *J Clin Oncol* 2008, **26**(4):620–625.
46. Dematteo RP, et al: Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). *Cancer* 2008, **112**(3):608–615.
47. Kang B, et al: A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors. *ASCO Meeting Abstracts* 2009, **27**(15S):e21515.
48. Joensuu H, et al: One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. *JAMA* 2012, **307**(12):1265–1272.
49. Sanon M, et al: Cost-effectiveness of three years of adjuvant imatinib in gastrointestinal stromal tumors (GIST). *ASCO Meeting Abstracts* 2012, **30**(4_suppl):137.
50. Deflin M, et al: Comparison of the clinical benefit of an adjuvant therapy in gastrointestinal stromal tumors (GIST) with other adjuvant cancer therapies. *ASCO Meeting Abstracts* 2012, **30**(4_suppl):129.
51. Lang I, et al: Case 3. Resection of originally inoperable liver metastases of gastrointestinal stromal tumor after imatinib mesylate therapy. *J Clin Oncol* 2003, **21**(18):3538–3540.
52. Andtbacka RH, et al: Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. *Ann Surg Oncol* 2007, **14**(1):14–24.
53. Katz D, et al: Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor. *Anticancer Drugs* 2004, **15**(6):599–602.
54. Bonvalot S, et al: Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. *Ann Surg Oncol* 2006, **13**(12):1596–1603.
55. Raut CP, et al: Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. *J Clin Oncol* 2006, **24**(15):2325–2331.
56. Scaife CL, et al: Is there a role for surgery in patients with "unresectable" cKIT + gastrointestinal stromal tumors treated with imatinib mesylate? *Am J Surg* 2003, **186**(6):665–669.
57. Hohenberger P, et al: Indication and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST). *ASCO Meeting Abstracts* 2006, **24**(18_suppl):9500.
58. Eisenberg BL, et al: Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. *J Surg Oncol* 2009, **99**(1):42–47.
59. Wang D, et al: Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. *Ann Surg Oncol* 2012, **19**(4):1074–1080.
60. Machlenkin S, et al: The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour. *Colorectal Dis* 2011, **13**(10):1110–1115.
61. McAuliffe JC, et al: A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. *Ann Surg Oncol* 2009, **16**(4):910–919.
62. DeMatteo RP: Neoadjuvant therapy of gastrointestinal stromal tumor (GIST). *Ann Surg Oncol* 2009, **16**(4):799–800.
63. Casali PG, et al: Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol* 2009, **20**(Suppl 4):64–67.
64. Plaat BE, et al: Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. *J Clin Oncol* 2000, **18**(18):3211–3220.
65. Druker BJ, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. *Nat Med* 1996, **2**(5):561–566.
66. Buchdunger E, et al: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. *Cancer Res* 1996, **56**(1):100–104.
67. Buchdunger E, et al: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. *J Pharmacol Exp Ther* 2000, **295**(1):139–145.
68. Demetri GD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med* 2002, **347**(7):472–480.
69. van Oosterom AT, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. *Lancet* 2001, **358**(9291):1421–1423.
70. Verweij J, et al: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. *Lancet* 2004, **364**(9440):1127–1134.
71. Van Glabbeke M, et al: Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. *J Clin Oncol* 2005, **23**(24):5795–5804.
72. Rutkowski P, et al: Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). *J Cancer Res Clin Oncol* 2007, **133**(9):589–597.
73. Armbrust T, et al: Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? - single center experience. *Eur J Gastroenterol Hepatol* 2009, **21**(7):819–823.

74. Heinrich MC, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. *J Clin Oncol* 2003, **21**(23):4342-4349.
75. Debiec-Rychter M, et al: Use of c-KIT/PDGFR α mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer* 2004, **40**(5):689-695.
76. Corless CL, et al: PDGFR α mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. *J Clin Oncol* 2005, **23**(23):5357-5364.
77. Heinrich MC, et al: Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. *J Clin Oncol* 2008, **26**(33):5360-5367.
78. Debiec-Rychter M, et al: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. *Eur J Cancer* 2006, **42**(8):1093-1103.
79. Van Glabbeke MM, et al: Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analysis based on 1,640 patients (pts). *ASCO Meeting Abstracts* 2007, **25**(18_suppl):10004.
80. Blay JY, et al: Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. *J Clin Oncol* 2007, **25**(9):1107-1113.
81. Le Cesne A, et al: Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. *Lancet Oncol* 2010, **11**(10):942-949.
82. Blay JY, Perol D, Le Cesne A: Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors. *Ann Oncol* 2012, **23**. doi:10.1093/annonc/mdr622.
83. Domont J, et al: Influence of imatinib interruption and imatinib rechallenge on the residual tumor volume in patients with advanced GIST: Results of the BFR14 prospective French Sarcoma Group randomized phase III trial. *ASCO Meeting Abstracts* 2011, **29**(15_suppl):10054.
84. Stroobants S, et al: 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). *Eur J Cancer* 2003, **39**(14):2012-2020.
85. Antoch G, et al: Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. *J Nucl Med* 2004, **45**(3):357-365.
86. Van den Abbeele AD, Badawi RD: Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). *Eur J Cancer* 2002, **38**(Suppl 5):S60-S65.
87. Benjamin RS, et al: We should desist using RECIST, at least in GIST. *J Clin Oncol* 2007, **25**(13):1760-1764.
88. Joensuu H, et al: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. *N Engl J Med* 2001, **344**(14):1052-1056.
89. Bechtold RE, et al: Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec. *Abdom Imaging* 2003, **28**(6):808-814.
90. Linton KM, Taylor MB, Radford JA: Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases. *Br J Radiol* 2006, **79**(944):e40-e44.
91. Heinrich MC, et al: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. *J Clin Oncol* 2006, **24**(29):4764-4774.
92. Desai J, et al: Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. *Clin Cancer Res* 2007, **13**(18 Pt 1):5398-5405.
93. Echoute K, et al: Drug transporters and imatinib treatment: implications for clinical practice. *Clin Cancer Res* 2011, **17**(3):406-415.
94. Shankar S, et al: Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. *Radiology* 2005, **235**(3):892-898.
95. Debiec-Rychter M, et al: Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. *Gastroenterology* 2005, **128**(2):270-279.
96. Demetri GD, et al: Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. *Clin Cancer Res* 2009, **15**(18):5902-5909.
97. Heinrich MC, et al: Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. *J Clin Oncol* 2008, **26**(33):5352-5359.
98. Demetri GD, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet* 2006, **368**(9544):1329-1338.
99. Guo T, et al: Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. *Clin Cancer Res* 2009, **15**(22):6862-6870.
100. Joensuu H, et al: Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. *Ann Oncol* 2008, **19**(1):173-177.
101. Montemurro M, et al: Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. *Eur J Cancer* 2009, **45**(13):2293-2297.
102. Dewaele B, et al: Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. *Clin Cancer Res* 2008, **14**(18):5749-5758.
103. Demetri GD, et al: A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. *Clin Cancer Res* 2009, **15**(18):5910-5916.
104. Benjamin RS, et al: Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. *Cancer Chemother Pharmacol* 2011, **68**(1):69-77.
105. Wiebe L, et al: Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium. *ASCO Meeting Abstracts* 2008, **26**(15_suppl):10502.
106. Campbell NP, et al: Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST). *ASCO Meeting Abstracts* 2011, **29**(4_suppl):4.
107. Reichardt P, et al: Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. *Ann Oncol* 2012, **23**. doi:10.1093/annonc/mdr598.
108. Schoffski P, et al: A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. *Ann Oncol* 2010, **21**(10):1990-1998.
109. Bauer S, et al: Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. *Cancer Res* 2006, **66**(18):9153-9161.
110. Demetri GD, et al: An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST. *ASCO Meeting Abstracts* 2011, **29**(15_suppl):10011.
111. Mazurenko NN, et al: Prognostic relevance of genetic aberrations in gastrointestinal stromal tumors. *ASCO GI Cancer Symposium* 2011, **29**(Suppl 4):49.
112. Watanabe T, et al: Impact of c-kit mutations, including codons 557 and/or 558, on the recurrence-free survival after curative surgery in patients with GIST. *ASCO GI Cancer Symposium* 2011, **29**(Suppl 4):12.
113. George S, et al: Hypertension (HTN) as a potential biomarker of efficacy in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU). *ASCO GI Cancer Symposium* 2011, **29**(Suppl 4):38.
114. Yoshikawa K, et al: The utility of PET-CT in predicting malignant potential of GIST. *ASCO GI Cancer Symposium* 2012, **30**(Suppl 4):38.
115. Seligmann JF, et al: D-dimers as a tumor marker in GIST: Can it reduce the frequency of CT scanning in patients receiving palliative imatinib? *ASCO GI Cancer Symposium* 2012, **30**(Suppl 4):119.
116. Bilimoria KY, et al: Incorporation of adjuvant therapy into the multimodality management of gastrointestinal stromal tumors of the stomach in the United States. *Ann Surg Oncol* 2012, **19**(1):184-191.
117. Witkowski ER, et al: Nationwide trends in diagnosis and outcomes of gastrointestinal stromal tumors in the era of targeted therapy. *ASCO GI Cancer Symposium* 2011, **29**(Suppl 4):121.

118. Italiano A, *et al*: Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib. *Ann Surg Oncol* 2012, **19**(5):1551–1559.
119. Blesius A, *et al*: Who are the long responders to imatinib (IM) in patients with advanced GIST? Results of the BFR14 prospective French Sarcoma Group randomized phase III trial. *ASCO Meeting Abstracts* 2011, **29**(15_suppl):10048.
120. Bertucci F, *et al*: Prognostic factors for progression-free and overall survival in patients with advanced GIST treated with standard-dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group. *ASCO Meeting Abstracts* 2011, **29**(15_suppl):e20506.
121. Yuan Y, *et al*: Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. *J Hematol Oncol* 2011, **4**:16.
122. Tan J, *et al*: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. *J Hematol Oncol* 2010, **3**(1):5.
123. Fremin C, Meloche S: From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. *J Hematol Oncol* 2010, **3**(1):8.
124. Elbaz H, *et al*: Digitoxin and its analogs as novel cancer therapeutics. *Exp Hematol Oncol* 2012, **1**(1):4.

doi:10.1186/2162-3619-1-14

Cite this article as: Lamba *et al*: Current management and prognostic features for gastrointestinal stromal tumor (GIST). *Experimental Hematology & Oncology* 2012 **1**:14.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

